The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Its a cash lock in unless you are willing to wait as this a a proper investment. Last fundraise was 80p about 6 months ago. Lots of people topped up around 23 to 24p i guess. Others will have waited for the seller to clear so maybe added at around 26 to 27p.
Traders have this for now. Lets see if they last the day...I guess they will be back tomorrow.
Private investors jumping in on a 6% rise is just gonna burn their cash. I think 20p or there about's by Friday. If it bounces then I'll buy Scancell which is about to fly IMO.
about Angle? What is a good entry point? Looks like 20p by Friday imo sad to say. If the selling does not slow then maybe less!
We have received feedback on Telegram that the tone is due to NOMAD (heavy hint). No doubt the initial heavy drop triggered institutional sells.
Thing is that Parsortix is so utterly brilliant in different applications it is rather difficult to know which to commercialise first!
However, the update indicates to me that the board are honing in on the most likely candidates. No doubt they realise they have to use the cash very wisely to make the best gains
1. Abbott collaboration MBC?
2. Solaris Prostate collaboration?
3. Ovarian LDT.
Likely on a personalised cancer care proposition.
All the other smaller studies have down the seeds and groundwork for other cancer types.
Start up business's such as this are budgeted for a loss over several years.
In order to generate eventual multi million pound revenues and maybe even profits. Business must engage in development, roll out, and marketing to name but a few items that cost many millions. Trading on public markets is not cheap and as you appreciate other regulatory cost's such as FDA, CLIA, ISO and many other things all come at a cost. Ever wondered how much it cost to get Parsortix through a rigorous process with FDA? How much do studies and trials cost to arrive at a successful conclusion?
The reason low or no revenue companies such as this (I would include most AIM companies in this category) rely on fund raising is to fill the gap until revenues arrive in sufficient volume to not only break even, but to make a profit. This is basic business and should have already formed the foundation of your research!! It really should come as no surprise you any of you that funds will need raising in the future.
And to the derampers. I would point out that in the entire history of Angle is has seen hardly any dillution and currently has no debt! Not only this but it has been an habitual achiever especially in the last 8 months.
But no, you make your own decisions. Don't let a little word like fact get in the way!
Fair question MJ!
It’s very nuanced IMO. Parsortix most likely would work on personalised cancer care for example. Scancell n the other hand may not be so dependant as they appear to be taking a broader approach.
There definitely is a place for Parsortix. The Solaris Prostate study may be a game changer for Angle if they follow through with a test for its 720k patients
Winit,
Love what RedX are doing but if it were them they would have issued an RNS. I dont think we should speculate or generate an OT. Lets just accept that who ever it was they have saved the gentlemans life and defeated cancer.